HK1118309A1 - Compositions and methods for humanization and optimization of n-glycans in plants - Google Patents

Compositions and methods for humanization and optimization of n-glycans in plants

Info

Publication number
HK1118309A1
HK1118309A1 HK08111335.3A HK08111335A HK1118309A1 HK 1118309 A1 HK1118309 A1 HK 1118309A1 HK 08111335 A HK08111335 A HK 08111335A HK 1118309 A1 HK1118309 A1 HK 1118309A1
Authority
HK
Hong Kong
Prior art keywords
glycans
humanization
optimization
plants
compositions
Prior art date
Application number
HK08111335.3A
Other languages
English (en)
Inventor
Lynn F Dickey
Kevin M Cox
Charles G Peele
Original Assignee
Synthon Biopharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Biopharmaceuticals Bv filed Critical Synthon Biopharmaceuticals Bv
Publication of HK1118309A1 publication Critical patent/HK1118309A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
HK08111335.3A 2006-01-17 2008-10-14 Compositions and methods for humanization and optimization of n-glycans in plants HK1118309A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75929806P 2006-01-17 2006-01-17
US79037306P 2006-04-07 2006-04-07
US79117806P 2006-04-11 2006-04-11
US81270206P 2006-06-09 2006-06-09
US83699806P 2006-08-11 2006-08-11
US86035806P 2006-11-21 2006-11-21
PCT/US2007/060642 WO2007084922A2 (en) 2006-01-17 2007-01-17 Compositions and methods for humanization and optimization of n-glycans in plants

Publications (1)

Publication Number Publication Date
HK1118309A1 true HK1118309A1 (en) 2009-02-06

Family

ID=38288381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111335.3A HK1118309A1 (en) 2006-01-17 2008-10-14 Compositions and methods for humanization and optimization of n-glycans in plants

Country Status (14)

Country Link
US (3) US8716557B2 (ko)
EP (2) EP1973940A2 (ko)
JP (2) JP2009526520A (ko)
KR (2) KR20080094064A (ko)
AU (2) AU2007205935B2 (ko)
BR (2) BRPI0707290A2 (ko)
CA (2) CA2637252A1 (ko)
DK (1) DK1974040T3 (ko)
ES (1) ES2395842T3 (ko)
HK (1) HK1118309A1 (ko)
IL (2) IL192761A0 (ko)
MX (2) MX2008009221A (ko)
NZ (2) NZ598048A (ko)
WO (2) WO2007084926A2 (ko)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976883B1 (en) * 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
AU2007205935B2 (en) * 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
EP1905825A1 (en) * 2006-09-29 2008-04-02 greenovation Biotech GmbH Galactosyltransferase
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
CN101641115B (zh) 2007-03-08 2013-04-24 卡罗拜奥斯制药公司 用于实体瘤治疗的EphA3抗体
US20100242128A1 (en) * 2007-10-31 2010-09-23 Bayer BioSceince NV Method to produce modified plants with altered n-glycosylation pattern
JP2010029102A (ja) * 2008-07-29 2010-02-12 Katakura Industries Co Ltd α１，３−フコシルトランスフェラーゼ
JP5435535B2 (ja) * 2008-08-30 2014-03-05 独立行政法人産業技術総合研究所 植物における糖鎖構造の改変方法及びその植物体
EP2379598B1 (en) 2009-01-19 2015-03-11 Innate Pharma Anti-kir3d antibodies
EP2400984A4 (en) * 2009-02-25 2013-01-23 Merck Sharp & Dohme HER2 ANTIBODY COMPOSITIONS
WO2010102244A1 (en) 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
EP2445336A2 (en) 2009-06-23 2012-05-02 Biolex Therapeutics, Inc. Methods and compositions for the cryopreservation of duckweed
CA2794037A1 (en) * 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
KR101293658B1 (ko) * 2010-12-30 2013-08-07 대한민국 알파-1,3-푸코실트랜스퍼라아제 및/또는 베타-1,2-자일로실트렌스퍼라아제 유전자를 포함하는 벼 형질전환용 벡터 및 형질전환된 벼
RU2711936C2 (ru) 2011-01-17 2020-01-23 Филип Моррис Продактс С.А. Экспрессия белка в растениях
JP6073247B2 (ja) * 2011-01-17 2017-02-01 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 植物で核酸を発現させるベクター
EP2673373B3 (en) 2011-02-08 2021-06-02 MedImmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012125720A2 (en) * 2011-03-14 2012-09-20 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
CA2862101A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
EP2912060B1 (en) * 2012-10-29 2019-12-25 The University of North Carolina at Chapel Hill Compositions and methods for inhibiting pathogen infection
EP2914094B1 (en) 2012-11-01 2021-07-21 Cellectis Plants for production of therapeutic proteins
EP2956169B1 (en) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
EP3255062B1 (en) 2013-02-14 2019-07-03 Innate Pharma Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl)
EP2958941B1 (en) 2013-02-20 2019-04-10 Innate Pharma A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
JP2013143969A (ja) * 2013-04-30 2013-07-25 National Institute Of Advanced Industrial Science & Technology 植物における糖鎖構造の改変方法及びその植物体
AR096236A1 (es) 2013-05-09 2015-12-16 The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
AU2014329609B2 (en) 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
AU2015289805B2 (en) 2014-07-15 2020-06-25 Humabs Biomed Sa Neutralizing anti-influenza B antibodies and uses thereof
KR101606918B1 (ko) * 2014-08-04 2016-03-28 경상대학교산학협력단 인간화 저-만노스형 엔-당질 합성 식물 및 이의 용도
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
NZ730247A (en) 2014-10-01 2022-11-25 Medimmune Ltd Antibodies to ticagrelor and methods of use
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EA038931B9 (ru) * 2014-11-20 2022-02-18 Йиссум Рисерч Дивелопмент Компани Оф Зе Хебрю Юниверсити Оф Иерусалим Лтд. Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
EP3265567B1 (en) 2015-03-02 2020-07-29 Conagen Inc. Regulatory elements from labyrinthulomycetes microorganisms
MA42043A (fr) 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
DK3303384T3 (da) 2015-06-01 2021-10-18 Medimmune Llc Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
WO2017004168A1 (en) 2015-06-29 2017-01-05 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
EP3430047A1 (en) 2016-03-15 2019-01-23 Innate Pharma Anti-mica antibodies
AU2017235543B2 (en) 2016-03-16 2020-05-14 Conagen, Inc. Production of proteins in labyrinthulomycetes
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
WO2018037000A1 (en) 2016-08-23 2018-03-01 Medimmune Limited Anti-vegf-a and anti-ang2 antibodies and uses thereof
EP3504236B1 (en) 2016-08-23 2020-09-23 Medimmune Limited Anti-vegf-a antibodies and uses thereof
WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
US20190248895A1 (en) 2016-10-21 2019-08-15 Innate Pharma Treatment with anti-kir3dl2 agents
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
EP3535385A4 (en) * 2016-11-01 2020-06-17 Conagen Inc. EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES
EP3548612A4 (en) 2016-12-01 2020-04-15 Plantform Corporation TRANSGENIC PLANT WITH REDUCED FUCOSYL TRANSFERASE AND XYLOSYL TRANSFERASE ACTIVITY
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
WO2018219956A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019040780A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics Inc. ANTI-B7-H4 ANTIBODIES AND METHODS OF USE
SG11202007820QA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody dosing regimens
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
AU2019228600A1 (en) 2018-03-02 2020-09-24 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
AU2019361923A1 (en) 2018-10-15 2021-06-03 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2020190834A1 (en) * 2019-03-18 2020-09-24 Score Pharma, Inc. Compounds for inhibiting fucosylation and methods for using the same
WO2021101351A2 (ko) * 2019-11-21 2021-05-27 (주)지플러스 생명과학 비푸코실화된 담배를 이용하여 생산한 항체 및 이의 용도
KR20230010749A (ko) 2020-05-17 2023-01-19 아스트라제네카 유케이 리미티드 Sars-cov-2 항체 및 이를 선택 및 이용하는 방법
JP2023537078A (ja) 2020-08-10 2023-08-30 アストラゼネカ・ユーケイ・リミテッド ＣＯＶＩＤ－１９を治療及び防止するためのＳＡＲＳ－ＣｏＶ－２抗体
US11277658B1 (en) 2020-08-21 2022-03-15 Beam, Inc. Integrating overlaid digital content into displayed data via graphics processing circuitry
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
US11475610B1 (en) 2021-04-30 2022-10-18 Mobeus Industries, Inc. Controlling interactivity of digital content overlaid onto displayed data via graphics processing circuitry using a frame buffer
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
KR20230105738A (ko) 2022-01-04 2023-07-12 (주)지플러스생명과학 당쇄 구조가 변형된 식물로부터 생산된 SARS-CoV-2의 스파이크 단백질의 수용체 결합 도메인 및 이의 용도
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
KR20240066509A (ko) * 2022-11-02 2024-05-16 주식회사 피토맵 N-당질화 돌연변이 벼를 이용한 단일클론항체 생산용 벼의 제조방법 및 이에 의해 제조된 단일클론항체

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81737A (en) 1986-03-28 1992-11-15 Calgene Inc Regulation of gene expression in plant cells
AU4770093A (en) 1992-07-02 1994-01-31 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
AU710874B2 (en) 1995-06-30 1999-09-30 Dna Plant Technology Corporation Delayed ripening tomato plants
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US7161064B2 (en) * 1997-08-12 2007-01-09 North Carolina State University Method for producing stably transformed duckweed using microprojectile bombardment
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ATE526406T1 (de) 1998-03-20 2011-10-15 Commw Scient Ind Res Org Kontrolle der genexpression
CN1202246C (zh) 1998-04-08 2005-05-18 联邦科学和工业研究组织 获得修饰表型的方法和措施
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US7019195B1 (en) * 1998-05-26 2006-03-28 Syngenta Participations Ag Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
AU771908C (en) * 1998-12-09 2005-03-10 Phyton Holdings, Llc A method for manufacturing glycoproteins having human-type glycosylation
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
AT408446B (de) 1999-02-18 2001-11-26 Altmann Friedrich Dr Fucosyltransferase-gen
WO2000049035A1 (en) 1999-02-19 2000-08-24 The General Hospital Corporation Gene silencing
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2001029242A2 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
IL149271A0 (en) 1999-10-26 2002-11-10 Plant Res Int Bv Mammalian-type glycosylation in plants
WO2001031044A1 (en) * 1999-10-26 2001-05-03 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Gonadotrophins in plants
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US20060029604A1 (en) 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
AU7684201A (en) * 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
JP2004532616A (ja) * 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
ZA200306406B (en) * 2001-01-19 2004-09-06 Dow Chemical Co Method for secretory production of glycoprotein having human-type sugar chain using plant cell.
CN1541059A (zh) 2001-03-06 2004-10-27 �Ϻ���ͨ��ѧ 具有动物型糖链加成功能的植物细胞
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
JP2003235561A (ja) 2002-02-21 2003-08-26 Kazuhito Fujiyama 植物型糖鎖を持つ糖タンパク質を動物型糖鎖を持つ糖タンパク質に変換する方法
CN1643147B (zh) 2002-03-14 2010-04-14 联邦科学和工业研究组织 监测和调节基因沉默的方法和工具
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
DE10224878A1 (de) * 2002-06-05 2004-01-08 Pall Corporation Filtereinsatz und Verfahren zu dessen Herstellung
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
US7781197B2 (en) 2002-12-20 2010-08-24 Greenovation Biotech Gmbh Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
EP1673394A4 (en) 2003-09-23 2008-03-26 Favrille Inc MODIFICATION OF A LYMPHOCYTE B PATHOLOGY USING AUTODERATED ANTIGENS IN CONJUGATION WITH A SPECIFICALLY BINDING CYTOREDUCING AGENT
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
CA2573745A1 (en) * 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
AU2005322617A1 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a Ga1G1cNAcMan5GlcNAc2 glycoform
WO2007028144A2 (en) 2005-09-02 2007-03-08 Glycofi, Inc Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
AU2007205935B2 (en) * 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
EP1976883B1 (en) 2006-01-17 2012-10-03 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies

Also Published As

Publication number Publication date
BRPI0707290A2 (pt) 2011-08-16
US20110144308A1 (en) 2011-06-16
CA2637252A1 (en) 2007-07-26
MX2008009221A (es) 2008-11-27
JP2009523432A (ja) 2009-06-25
US20080060092A1 (en) 2008-03-06
NZ598048A (en) 2013-05-31
AU2007205935A1 (en) 2007-07-26
WO2007084922A3 (en) 2008-03-06
KR20080094064A (ko) 2008-10-22
CA2637254A1 (en) 2007-07-26
NZ596322A (en) 2013-02-22
US20080066200A1 (en) 2008-03-13
WO2007084922A8 (en) 2009-07-23
EP1974040A2 (en) 2008-10-01
US7884264B2 (en) 2011-02-08
AU2007205939A1 (en) 2007-07-26
WO2007084926A3 (en) 2008-04-24
MX2008009220A (es) 2008-10-10
WO2007084922A2 (en) 2007-07-26
WO2007084926A2 (en) 2007-07-26
IL192761A0 (en) 2011-08-01
BRPI0707289A2 (pt) 2011-04-26
EP1974040B1 (en) 2012-10-03
ES2395842T3 (es) 2013-02-15
AU2007205935B2 (en) 2013-07-11
KR20080094918A (ko) 2008-10-27
JP2009526520A (ja) 2009-07-23
AU2007205939B2 (en) 2012-12-13
DK1974040T3 (da) 2012-12-17
US8716557B2 (en) 2014-05-06
IL192802A0 (en) 2009-02-11
EP1973940A2 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
HK1118309A1 (en) Compositions and methods for humanization and optimization of n-glycans in plants
AP2885A (en) Methods and compositions for improving plant health
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
HK1137670A1 (en) Compositions and methods for arthrodetic procedures
EP2130435B8 (en) Agent for improving alkali resistance of plant and method for improving alkali resistance of plant
SG10201405107YA (en) Compositions and methods useful for culturing differentiable cells
HK1143173A1 (en) Compositions and methods for use of antibodies against sclerostin
IL193345A0 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
ZA200901133B (en) Methods and systems for designing animal food compositions
ZA200906387B (en) Compositions and methods for enhancing the development of growing animals
EP2041266A4 (en) COMPOSITIONS AND METHOD FOR BUTANEAN MANUFACTURE
HK1129849A1 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
ZA200809504B (en) Methods and compositions for obtaining marker-free transgenic plants
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
SI2048935T1 (sl) Postopek za gojenje rastlin
EP2294199A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING PLANTS
PL2048937T3 (pl) Sposób uprawy roślin
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
IL205248A0 (en) Compositions and methods for making androstenediones
GB0605247D0 (en) Compositions and methods for immunisation
PL2294198T3 (pl) Sposoby i kompozycje do ulepszania roślin
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
EP1963485A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING PLANT GROWTH

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170117